TCM
BMRN icon

TAM Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

TAM Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-52,180
Closed -$4.23M – 10
2018
Q1 		$4.23M Buy
+52,180
New +$4.48M 4% 7

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

TAM Capital Management's BMRN Position: Q2 2018 in Review

TAM Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 52,180 shares — an estimated $4.23M sold.

TAM Capital Management first reported a position in BMRN in Q1 2018 and held it in 1 quarter. The position peaked at $4.23M in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • TAM Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • TAM Capital Management sold 52,180 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $4.23M.
  • TAM Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • TAM Capital Management's BioMarin Pharmaceuticals position peaked at $4.23M in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on TAM Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.